Ask about this productRelated genes to: CD1A antibody
- Gene:
- CD1A NIH gene
- Name:
- CD1a molecule
- Previous symbol:
- CD1
- Synonyms:
- -
- Chromosome:
- 1q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 1988-05-11
- Date modifiied:
- 2017-07-07
Related products to: CD1A antibody
Related articles to: CD1A antibody
- A 49-year-old man presented with a 1-year history of red facial nodules and a 3-month history of left-sided hearing decline. A biopsy revealed mixed inflammation and emperipolesis of histiocyte-like cells. An immunohistochemical analysis demonstrated that the histiocyte-like cells were positive for S100 and CD68 and negative for CD1a and CD207, confirming the diagnosis of cutaneous Rosai-Dorfman disease (CRDD). The initial treatment consisted of oral prednisone acetate combined with methotrexate. Due to limited efficacy and adverse effects, methotrexate was discontinued, and prednisone acetate monotherapy was used. After 2 months, the patient's skin lesions gradually resolved, and hearing improved. This case demonstrates that CRDD involving the ear can lead to hearing recovery following systemic corticosteroid therapy. - Source: PubMed
Publication date: 2026/04/21
Zhuo XiaoxueDangzeng ZhuomaZhou PeiyuWang TingtingWang Lin - Epithelioid fibrous histiocytoma (EFH) is a benign cutaneous neoplasm that is now recognized to be largely driven by rearrangements. Rare cases of EFH and EFH-spectrum tumors with other receptor tyrosine kinase (RTK) fusions including and have been described, demonstrating the molecular heterogeneity of this entity. Herein, we report a 9-year-old female with a 1.5 cm right lateral chest wall lesion showing classic EFH morphology. Histology demonstrated a nodular dermal tumor extending to dermo-epidermal junction above and subcutaneous tissue below. The lesion was characterized by sheets of bland epithelioid/histiocytoid cells with a vaguely whorled architecture, prominent vessels, focal myxoid stroma, and no significant atypia, mitoses, or necrosis. On immunohistochemistry, the lesional cells were highlighted by CD68 and CD163, with patchy CD99 positivity. The lesional cells were negative for AE1/AE3, CD34, SMA, Desmin, S100, SOX10, CD10, ERG, CD1a, Langerin, CD30, and CD31. INI-1 was retained. Targeted solid tumor fusion analysis showed an fusion. This case expands the molecular spectrum of EFH beyond rearrangements and previously described and fusions. - Source: PubMed
Publication date: 2026/05/05
Challa BinduNaous RanaKirschner RichardReshmi Shalini CPrasad Vinay - Erdheim-Chester Disease (ECD) and Rosai-Dorfman Disease (RDD) Are Rare Non-Langerhans Cell Histiocytoses That Share Several Clinical and Histological Features, Including the Accumulation of CD1a- Histiocytes in Organs. Cladribine, a Purine Analog, Leads to an Overall Response Rate (ORR) of 91% in Langerhans-Cell Histiocytoses. Whether the Same Results Could Be Obtained in Non-Langerhans Cell Histiocytoses Remains To Be Determined. - Source: PubMed
Publication date: 2026/05/04
Riller QuentinBen Salem ThourayaEmile Jean-FrançoisCharlotte FrédéricIdbaih AhmedFaucher BenoîtDe Almeida SébastienMartin-Blondel GuillaumeTazi AbdellatifDonadieu JeanRiviere EtienneSamson MaximeSouffir CamilleAmoura ZahirHaroche JulienCohen-Aubart Fleur - ContextRosai-Dorfman disease is a rare histiocytic disorder that primarily affects lymph nodes but may present at extranodal sites. Breast involvement is exceptionally rare and often mimics malignancy on clinical and imaging studies, leading to diagnostic challenges.ObjectiveTo describe the clinical, radiologic, and pathologic features of breast Rosai-Dorfman disease and review management outcomes.DesignWe retrospectively reviewed all instances of breast Rosai-Dorfman disease diagnosed at our institution over a 14-month period. Clinical records, imaging studies, histopathology, treatment, and follow-up data were analyzed.ResultsA total of three patients were diagnosed with Rosai-Dorfman disease of the breast. All three patients were women aged 22 to 71 years. Two presented with palpable breast masses, and one patient had a mass that was incidentally detected on chest computed tomography. Imaging demonstrated irregular masses categorized as Breast Imaging Reporting and Data System (BI-RADS) category 4-5, suspicious for carcinoma. Histopathologic examination showed dense lymphoplasmacytic infiltrates with histiocytes exhibiting emperipolesis and immunoreactivity for S100, CD68, and CD163, with negative CD1A staining. Two patients underwent excision, and one was managed conservatively. At follow-up, all patients remained disease-free without recurrence or systemic involvement.ConclusionsBreast Rosai-Dorfman disease is a rare benign entity that closely mimics carcinoma both clinically and radiologically. Accurate diagnosis relies on histopathologic evaluation with immunohistochemistry. Management may range from observation to surgical excision depending on lesion size and symptoms. Awareness of this presentation is essential to prevent misdiagnosis and overtreatment. - Source: PubMed
Publication date: 2026/05/04
Hernandez Guzman Alba RebeccaMalerba RominaRong YuanAkhtar IsrahBains AshishNasibli JalilGonzalez Maria F - Rosai-Dorfman disease, also known as sinus histiocytosis with massive lymphadenopathy, is a rare non-Langerhans cell histiocytic disorder most commonly involving the cervical lymph nodes, which are affected in approximately 80%-90% of cases. It predominantly affects children and young adults but may occur at any age, typically presenting with painless, bilateral, and sometimes bulky cervical lymphadenopathy, occasionally associated with systemic inflammatory symptoms and laboratory abnormalities such as elevated inflammatory markers and polyclonal hypergammaglobulinemia. Histopathological examination is essential for diagnosis and demonstrates marked sinus expansion by large histiocytes with abundant pale cytoplasm and characteristic emperipolesis, set within a lymphoplasmacytic background. Immunohistochemically, these histiocytes express CD68, CD163, and S100 protein, while lacking CD1a and langerin expression, allowing distinction from other histiocytic disorders. Although historically considered a benign reactive condition, recent molecular studies have identified activating mutations in the MAPK/ERK signaling pathway, including , and , in a significant subset of cases, supporting a clonal neoplastic component. The clinical course of cervical RDD is generally favorable, and management is individualized, ranging from observation to surgical excision in cases of compressive symptoms, with systemic or targeted therapies reserved for refractory or multisystem disease. We report the case of a 25-year-old patient with no significant past medical history who presented with a persistent cervical lymphadenopathy. Comprehensive clinical evaluation, laboratory investigations, and imaging studies supported the diagnosis of Rosai-Dorfman disease. Prompt recognition and appropriate surgical management play a crucial role in achieving favorable clinical outcomes. - Source: PubMed
Publication date: 2026/04/22
Rguyeg AbdelilahBoutahar MohamedLachkar Azeddine